Compare Expensify Inc (EXFY) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Nuvalent Inc — how do they compare? Expensify Inc trades at $1.8 (market cap $170.21M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 57.6× Expensify Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | NUVL | |
|---|---|---|
Market Cap | $170.21M | $9.81B |
Sector | Technology | Technology |
52-Week High | $2.33 | $123.96 |
52-Week Low | $0.75 | $72.16 |
Enterprise Value | $109.24M | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.77, down 2.21% on the day, with a bullish technical signal from moving averages but mixed earnings history. Revenue for 2025 was $142.10M, but the company posted a net loss of -$21.39M, with negative profit margins and ROE. Recent news highlights product innovations like AI-powered expense automation and a $25M stock buyback program, indicating active management efforts to drive growth and shareholder value.
The outlook remains challenging due to persistent unprofitability, though positive cash flow from operations and strategic partnerships offer some stability. Investment opportunities hinge on successful execution of new AI and travel billing initiatives to improve margins. Key risks include intense competition in expense management software and the company's ability to achieve sustained profitability amid fluctuating revenues.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.
The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
